https://www.businessline.global/brii-biosciences-vir-biotechnology-and-vbi-vaccines-announce-initiation-of-phase-2-clinical-trial-of-brii-835-vir-2218-in-combination-with-brii-179-vbi-2601-for-the-treatment-of-hepatitis-b/press-release/